Bluejay Diagnostics Files 8-K with Financials

Ticker: BJDX · Form: 8-K · Filed: 2025-06-04T00:00:00.000Z

Sentiment: neutral

Topics: 8-K, financial-statements, exhibits

TL;DR

Bluejay Diagnostics dropped an 8-K with financials on 6/3/25.

AI Summary

On June 3, 2025, Bluejay Diagnostics, Inc. filed an 8-K report. The filing primarily concerns the submission of financial statements and exhibits, with no other specific events detailed in the provided text. The company is incorporated in Delaware and its principal executive offices are located in Acton, MA.

Why It Matters

This filing indicates that Bluejay Diagnostics is providing updated financial information and exhibits to the SEC, which is a standard regulatory requirement for public companies.

Risk Assessment

Risk Level: low — The filing is a routine 8-K report for financial statements and exhibits, with no indication of significant operational changes or negative events.

Key Numbers

Key Players & Entities

FAQ

What specific financial statements or exhibits are being filed with this 8-K?

The provided text states that the filing includes 'Financial Statements and Exhibits' but does not specify the exact nature or content of these documents.

Are there any material events reported in this 8-K beyond the filing of exhibits?

The filing is categorized under 'Other Events' and 'Financial Statements and Exhibits,' but the provided text does not detail any specific material events beyond the submission of these documents.

When was the earliest event reported in this 8-K?

The earliest event reported in this 8-K was on June 3, 2025.

What is Bluejay Diagnostics, Inc.'s principal executive office address?

Bluejay Diagnostics, Inc.'s principal executive offices are located at 360 Massachusetts Avenue, Suite 203, Acton, MA 01720.

What is the SIC code for Bluejay Diagnostics, Inc.?

The Standard Industrial Classification (SIC) code for Bluejay Diagnostics, Inc. is 3841, which corresponds to 'Surgical & Medical Instruments & Apparatus'.

From the Filing

0001213900-25-050913.txt : 20250604 0001213900-25-050913.hdr.sgml : 20250604 20250603201958 ACCESSION NUMBER: 0001213900-25-050913 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20250603 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250604 DATE AS OF CHANGE: 20250603 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Bluejay Diagnostics, Inc. CENTRAL INDEX KEY: 0001704287 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 473552922 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41031 FILM NUMBER: 251021585 BUSINESS ADDRESS: STREET 1: 360 MASSACHUSETTS AVENUE, SUITE 203 CITY: ACTON STATE: MA ZIP: 01720 BUSINESS PHONE: (978) 631-0152 MAIL ADDRESS: STREET 1: 360 MASSACHUSETTS AVENUE, SUITE 203 CITY: ACTON STATE: MA ZIP: 01720 8-K 1 ea0244646-8k_bluejay.htm CURRENT REPORT false 0001704287 0001704287 2025-06-03 2025-06-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549       FORM 8-K       CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): June 3, 2025         BLUEJAY DIAGNOSTICS, INC. (Exact Name of Registrant as Specified in its Charter)   delaware   001-41031   47-3552922 (State or Other Jurisdiction of Incorporation or Organization)   (Commission File No.)   (I.R.S. Employer Identification No.)   360 Massachusetts Avenue , Suite 203 Acton ,  MA   01720 (Address of principal executive offices and zip code)   ( 844 )  327-7078 (Registrant’s telephone number, including area code)     (Former name or former address, if changed from last report)       Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c))   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company  ☒   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol (s)   Name of each exchange on which registered Common Stock, par value $0.0001 per share   BJDX   The Nasdaq Capital Market           Item 8.01 Other Events.   On June 3, 2025, Bluejay Diagnostics, Inc. issued a press release providing a 2025 mid-year business and corporate update. A copy of that press release is filed herewith as Exhibit 99.1 and incorporated herein by reference.   Item 9.01. Financial Statements and Exhibits.   (d) Exhibits   99.1   Press release, dated June 3, 2025

View on Read The Filing